公开(公告)号：EP0321185A2

公开(公告)日：1989-06-21

申请号：EP88311785.5

申请日：1988-12-13

申请人： BEECHAM GROUP PLC

发明人： Davies, John Sidney

IPC分类号： C07H17/08 ,  A61K31/70

CPC分类号： C07H17/08

摘要： 9- N ,11- O -methylene derivatives of erythromycin-9-imine (wherein the methylene group is optionally substituted) of the general formula IA or IB:
or a pharmaceutically acceptable ester or acid addition salt thereof,
wherein
R¹ denotes hydrogen, an unsubstituted or substituted hydrocarbon group, a heterocyclyl group, or an acyl group;
R³ denotes hydrogen or hydroxy;
R⁶ denotes hydrogen or methyl;
one of R⁷ and R⁸ denotes hydrogen, hydroxy, alkoxy,alkanoyloxy, amino, substituted amino, or a group of the formula R⁹-SO₂-O-, and the other of R⁷ and R⁸ denotes hydrogen, or
R⁷ and R⁸ together denote an oxo group, an oxime group, or a substituted oxime group; and
R⁹ denotes an organic group,
possess improved acid stability, compared with erythromycin A, whilst retaining good antibacterial activity.

摘要翻译： 通式IA或IB的红霉素-9-亚胺（其中亚甲基任选被取代）的9-N，11-O-亚甲基衍生物或其药学上可接受的酯或酸加成盐，其中R 1， 1>表示氢，未取代或取代的烃基，杂环基或酰基; R 3表示氢或羟基; R 6表示氢或甲基; R 7和R 8中的一个表示氢，羟基，烷氧基，烷酰氧基，氨基，取代的氨基或式R 9 -SO 2 -O-的基团，R 7和 R 8表示氢，或R 7和R 8一起表示氧代基，肟基或取代的肟基; R 9表示有机基团，与红霉素A相比具有改善的酸稳定性，同时保持良好的抗菌活性。

公开(公告)号：EP0321185A3

公开(公告)日：1989-11-02

申请号：EP88311785.5

申请日：1988-12-13

申请人： BEECHAM GROUP PLC

发明人： Davies, John Sidney

IPC分类号： C07H17/08 ,  A61K31/70

CPC分类号： C07H17/08

摘要： 9- N ,11- O -methylene derivatives of erythromycin-9-imine (wherein the methylene group is optionally substituted) of the general formula IA or IB:
or a pharmaceutically acceptable ester or acid addition salt thereof,
wherein
R¹ denotes hydrogen, an unsubstituted or substituted hydrocarbon group, a heterocyclyl group, or an acyl group;
R³ denotes hydrogen or hydroxy;
R⁶ denotes hydrogen or methyl;
one of R⁷ and R⁸ denotes hydrogen, hydroxy, alkoxy,alkanoyloxy, amino, substituted amino, or a group of the formula R⁹-SO₂-O-, and the other of R⁷ and R⁸ denotes hydrogen, or
R⁷ and R⁸ together denote an oxo group, an oxime group, or a substituted oxime group; and
R⁹ denotes an organic group,
possess improved acid stability, compared with erythromycin A, whilst retaining good antibacterial activity.

摘要翻译： 通式IA或IB的红霉素-9-亚胺（其中亚甲基任选被取代）的9-N，11-O-亚甲基衍生物或其药学上可接受的酯或酸加成盐，其中R 1， 1>表示氢，未取代或取代的烃基，杂环基或酰基; R 3表示氢或羟基; R 6表示氢或甲基; R 7和R 8中的一个表示氢，羟基，烷氧基，烷酰氧基，氨基，取代的氨基或式R 9 -SO 2 -O-的基团，R 7和 R 8表示氢，或R 7和R 8一起表示氧代基，肟基或取代的肟基; R 9表示有机基团，与红霉素A相比具有改善的酸稳定性，同时保持良好的抗菌活性。

公开(公告)号：EP0201166A1

公开(公告)日：1986-11-12

申请号：EP86301685.3

申请日：1986-03-10

申请人： BEECHAM GROUP PLC

发明人： Davies, John Sidney

IPC分类号： C07H17/08 ,  A61K31/70

CPC分类号： C07H17/08

摘要： 11-ether derivatives of erythromycin, and corresponding 9-(optionally substituted)-amino, 9-imino, and 9-(optionally substituted)-oxime derivatives are novel antibacterially active compounds, and can be prepared by alkylation of the 11-hydroxy group under mild conditions.

公开(公告)号：EP0201166B1

公开(公告)日：1990-02-07

申请号：EP86301685.3

申请日：1986-03-10

申请人： BEECHAM GROUP PLC

发明人： Davies, John Sidney

IPC分类号： C07H17/08 ,  A61K31/70

CPC分类号： C07H17/08

公开(公告)号：EP0084730A1

公开(公告)日：1983-08-03

申请号：EP82306882.0

申请日：1982-12-23

申请人： BEECHAM GROUP PLC

发明人： Davies, John Sidney ,  Hunter, Pamela Ann

IPC分类号： C07D499/32 ,  C07D519/00 ,  A61K31/43

CPC分类号： C07D499/00

摘要： Compounds, their salts and esters, of formula (I):
wherein R 1 is C 1-6 alkyl, C 3-8 cycloalkyl, C S-8 cycloalkenyl or an aromatic group;

X is oxygen or sulphur; m is zero or one; n is zero, one or two;
R 2 is hydrogen, acylamino, ureido, acylureido or guanidino; R 3 is the residue of a β-lactam containing β-lactamase inhibitor
R 3 C0 2 H; and R 4 is hydrogen or a hydrocarbon moiety; any of the above groups being optionally substituted;
are ε-lactamase inhibitors, and may be prepared by reacting together a source of

(a) the side-chain R 1 -(X) m -(CH 2 ) n -CHR 2 -CO-
(b) the 6-aminopenicillanic acid moiety; and
(c) the esterifying group -CHR 4 -O-CO-R 3 .
The compounds may be used to treat bacterial infections in animals such as those of the respiratory and urinary tracts, of soft tissues, or mastitis in cattle. They may be administered alone or together with a pharmaceutically acceptable carrier as
a pharmaceutical composition.

摘要翻译： 式（I）的化合物，其盐和酯：其中R 1是C 1-6烷基，C 3-8环烷基，C 5-8环烯基或芳基; X是氧或硫; m为零或一; n为零，一或二; R 2是氢，酰氨基，脲基，酰基脲基或胍基; R 3是含有β-内酰胺酶抑制剂R 3 CO 2 H的β-内酰胺的残基; 和R 4是氢或烃部分; 任何上述基团任选被取代; 是β-内酰胺酶抑制剂，并且可以通过使（a）侧链R 1 - （X）m - （CH 2）n -CHR 2 -CO-; （b）6-氨基青霉烷酸部分; 和（c）酯化基团-CHR 4 -O-CO-R 3。 该化合物可用于治疗动物中的细菌感染，例如呼吸道和尿道，软组织或牛中的乳腺炎。 它们可以单独施用或与作为药物组合物的药学上可接受的载体一起施用。